Real life experience of mycophenolate mofetil monotherapy in liver transplant patients - Université de Lille Accéder directement au contenu
Article Dans Une Revue Clinics and Research in Hepatology and Gastroenterology Année : 2021

Real life experience of mycophenolate mofetil monotherapy in liver transplant patients

Franck Saint-Marcoux
  • Fonction : Auteur
Guillaume Millet
Massih Ningarhari
  • Fonction : Auteur

Résumé

BACKGROUND: Mycophenolate mofetil (MMF) monotherapy following liver transplantation (LT) remains controversial due to a risk of acute rejection. The aim of this study was to report the largest multicenter experience of the use a MMF monotherapy guided by therapeutic drug monitoring using pharmacoslope modeling and Bayesian estimations of the MPA inter-dose AUC (BEMPAMETHODS: MMF daily doses were adjusted to reach the BEMPARESULTS: From 2000-2014, in 2 transplantation centers, 94 liver transplant recipients received MMF monotherapy 6.5±4 years after LT. The mean BEMPACONCLUSIONS: MMF monotherapy regimen appears usually safe and beneficial, with low risk of acute rejection and eGFR improvement. Therapeutic drug monitoring strategy seemed useful by identifying 14% of patients with low MMF exposure.
Fichier principal
Vignette du fichier
S2210740120301443.pdf (404.4 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03533970 , version 1 (03-02-2023)

Licence

Identifiants

Citer

Guillaume Lassailly, Jerome Dumortier, Franck Saint-Marcoux, Mehdi El Amrani, Juliette Boulanger, et al.. Real life experience of mycophenolate mofetil monotherapy in liver transplant patients. Clinics and Research in Hepatology and Gastroenterology, 2021, Clinics and research in hepatology and gastroenterology, 45 (1), pp.101451. ⟨10.1016/j.clinre.2020.04.017⟩. ⟨hal-03533970⟩
37 Consultations
60 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More